Abstract
Epstein-Barr Nuclear Antigen 1 (EBNA1), a dimeric oncoprotein of the Epstein-Barr virus (EBV), is essential for both viral-genome maintenance and the survival of infected cells. Despite EBNA1's potential as a therapeutic target, tools for the direct monitoring of EBNA1 in vitro and in vivo are lacking. Here, we show that a peptide-based inhibitor that luminesces when bound to EBNA1 inside the nucleus of EBV+ cells can regulate EBNA1 homodimer formation and selectively inhibit the growth of EBV+ tumours of nasopharyngeal carcinoma C666-1 cells, NPC43 cells and Burkitt's lymphoma Raji cells. We also show that the peptide-based probe leads to 93% growth inhibition of EBV+ tumours in mice. Our findings support the hypothesis that selective inhibition of EBNA1 dimerization can be used to afford better EBV-related cancer differentiation, and highlight the potential application of the probe as a new generation of biotracers for investigating the fundamental biological function of EBNA1 and for exploring its application as a therapeutic target.
P r o o f
Epstein-Barr virus (EBV) is a ubiquitous human herpes virus which causes both infectious mononucleosis and lymphoproliferative diseases 1,2 , but the virus is well controlled by the immune system once it establishes latent infection in human hosts 3, 4 . Epstein-Barr nuclear antigen 1 (EBNA1) is the only oncoprotein expressed in all EBV-positive tumours and it plays critical roles in the maintenance, replication and transcription of the EBV genome. Furthermore, it can influence cellular gene transcription which is fundamental in the development of EBV-related tumours 5 .
Given these key biological functions, EBNA1 has become an attractive target for therapeutic intervention 6, 7 . Considering that homodimerization of EBNA1 is essential for EBNA1 to function, inhibitors which can specifically prevent the dimerization process offer a novel avenue by which to target and kill EBV-positive cells 8, 9 . Several EBNA1 inhibitors have been reported to efficiently block EBNA1 homodimerization, including the small molecule, EiK1, and a short EBNA1 derived peptide (P85). Eik1 was identified via high-throughput screening, and it is capable of targeting the dimeric interface of EBNA1 (residues 459-607), P85 which contains a short EBNA1 derived 3 sheet (a.a. 560-566) also targets this region (residues 560-574) 8 . However, most of the EBNA1 targeting compounds that have been reported to date cannot be easily imaged (in vitro) and they have low bioavailability. Both the aforementioned issues present major challenges to the field and hamper the further development of EBNA1 targeting therapeutics. To overcome the nonfluorescent nature and poor water solubility of the previously reported EBNA1 inhibitors, we recently designed a novel hybrid system, which contained a charged, water-soluble chromophore and an EBNA1-specific peptide. The charged, water-soluble chromophore-peptide bio-conjugate, JLP2, enabled for the first time both simultaneous specific imaging and inhibition of EBNA1 in vitro 9 . However, JLP2 lacked specific subcellular localization and it displayed no responsive P r o o f binding which limited its further development as a tool for cellular imaging, and, as a potential selective therapeutic agent for the treatment of EBV cancers.
It is also worth noting that EBNA1 is primarily localized in the nucleus of EBV-positive cells 10 , and EBNA1 acts as a bridge between mitotic chromosomes and oriP-containing plasmids 11 . One factor that has limited the success of cancer therapies is the challenging associated with specifically targeting a desired cell type 12 . Despite the key role and the specific localization of EBNA1, a direct and sensitive system for visualizing EBNA1 in the nucleus and monitoring its effect on EBNA1 homodimerization is not currently available. To address this problem, we reasoned that valuable new insights and selective tumour inhibition both in vitro and in vivo could be gained if a nucleuspenetrating EBNA1-specific dual-probe could be developed. The development of responsive nucleus-specific bioprobes for in vitro microscopic studies of EBNA1 and selective inhibition on EBV-positive tumour has not yet been explored in detail. The work reported here offers a strategy for responsive-emission imaging in EBV-positive cells and provides highly selective and efficient in vitro/vivo cytotoxicity.
The rationale design ( Fig. 1a ) of the dual functioning probe was achieved using docking and molecular dynamic (MD) simulations and their synthesis was outlined in Sup. Fig. 1 . The characterization of all intermediates and final products, including 1 H NMR, 13 C NMR and Mass Spectra, were performed as shown in Sup. Fig. 37 -48. What's more, the peptide conjugates were purified via HPLC, the purification and characterization was recorded in Sup. Fig. 2-6 , the used solvent gradient was also recorded (Sup. Table 1 and 2). The strong interaction of L2P4 with the wild type EBNA1 (WT-EBNA1) was confirmed by a 8.8-fold increase in its emission intensity.
L2P4 responded significantly upon binding with WT-EBNA1, and the responsive signal was found to be induced by the intermolecular charge transfer (ICT) mechanism ( Both the in vitro and in vivo studies described here demonstrated the effectiveness of L2P4 as a dual EBV tumour-selective cancer targeting agent and responsive imaging probe. Given these findings, we envisage that L2P4 represents an efficient tool to delineate the processes that govern EBNA1 within the nucleus. In the longer term this new level of understanding will provide exciting new opportunities for the treatment of EBV-associated tumours, such as Hodgkin lymphoma, nasopharyngeal carcinoma and a sub-group of EBV-associated stomach cancer.

Results
Rational design and MD simulations between probes and EBNA1.
The X-ray crystal structure of EBNA1's DNA-binding domain (DBD) (PDB ID: 1B3T, chain A, residue 461 to 607) is α/β mixed fold comprised of 4 alpha helix and 4 beta sheet motifs which are linked by several loops ( Fig. 1b and Sup. Fig. 7 ) 13 . Different structural motifs contribute to its distinct functional regions: the beta sheets 1-4 (β1-β4) drive the formation of dimer via hydrophobic packing; the alpha helices 1 and 2 (α1, α2) interact with DNA via electrostatic interactions, while the alpha helices 3 and 4 (α3, α4) stabilize the beta sheets; the positively-charged loop 1 mediates DNA binding; and the flexible loop 5 also involves in the dimerization 14 .
The putative structure of EBNA1 DBD monomer was generated through the isolation from the Xray crystal structure of its homodimer, and it was performed for a 200 ns all-atom explicit solvent MD simulations. The putative structure demonstrated a good stability and kept the original conformation during the simulation, except for the highly dynamic loop 1 and 5 which have no contribution in the homodimerization of EBNA1 (Sup. Fig. 8a, 8b ). What's more, the 4 beta sheets which comprise the dimeric interface were also found to exhibit good stability (Sup. Fig. 8c ). It was further evaluated for the accessibility of the dimeric interface in the putative structure, and the results suggested that the key residues (Y561, M563, and F565) on the dimeric interface 8 could be assessed by extrinsic probes (Sup. Fig. 8d ). After checking the stability and accessibility of this putative structure, a representative conformation was selected out and the docking study was carried out to identify the best docked poses for each ligand-EBNA1complex (Sup. Fig. 8e, 8f ).
All docked poses were then ranked using a scoring function to choose the final poses for each complex. It was found most selected poses sharing some extend similarities, for example, the interaction of the key residues in EBNA1 to YFMVF appeared in all complexes (Sup. Fig. 9 ).
P r o o f
Besides, an unexpected salt-bridging was found between the positively-charged tetrapeptide RrRK and the aspartate-rich tail in EBNA1, suggesting a second role of the NLS.
To better characterize the ligand-EBNA1 complex and calculate their binding energy, a 200 ns MD simulations were then performed using the selected docked poses. The AMBER types of the non-standard residues were parameterized (Sup. Fig. 10 ) and the missing force filed parameters were defined (Sup. Table 3 ) prior to the following 200 ns MD simulations. All complexes were found to be stabilized after 50 ns, and it is hard to find a conserved binding pattern between them though sharing a same motif (YFMVF), and it is due to the affection of the salt-bridging interaction which appeared only in the ligands containing the RrRK tetrapeptide. Despite these, the main interactions suggested by MD simulations for each complex were similar (i.e. the clear hydrophobic contacts and the salt-bridging, Sup. Fig. 17 ). The hydrophobic interactions identified occurred between the key residues on the dimeric interface and the ligands, while the salt bridging was formed between the RrRK motif and several residues in the aspartate-rich tail in EBNA1 (D602, D601 and D605). In particular, D602 demonstrated the strongest salt bridging interaction and D605 showed the weakest (Sup. Fig. 11-16 ). Taken as a whole, the MD simulations suggested two major interaction type which facilitate the binding of the designed probes to EBNA1, and they also, demonstrated a secondary role of the RrRK sequence beyond nuclei targeting (Fig. 1b ).
The binding free energy for all complexes was calculated via Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) based on full trajectory. The calculated GB and PB values took the same order L2P4 > L2P3 > L2P2 ( Fig. 1c and Sup. Table 4 ), indicating that L2P4 is likely to have the strongest binding interaction among the three probes to EBNA1.
It should be noted that an X-ray crystal structure of the EBNA1 monomer has not yet been solved and that the use of a putative one could result in errors in the numerical data generated via MD
Responsive emission of L2P4 with EBNA1. The stability of L2P2-L2P4 was performed by monitoring their emission spectrum at 37 C during 24 hours, and all probes demonstrated a good stability in the simulated extra cellular anion mixture (PBS buffer) (Sup. Fig. 18 ). As discussed from the MD simulations and free energy calculations, L2P4 was predicted to have the strongest interaction with WT-EBNA1 of the three probes studied, and thus it potentially offered the best option by which to prevent the homodimerization of EBNA1 and ultimately inhibit the growth of EBV-positive tumour. To further assess the binding affinity of L2P4 to WT-EBNA1, luminescence titration experiment was carried out in PBS buffer. The results obtained from the titration experiment aligned well with the calculated data via MMPBSA. For example, L2P4 was found to have the strongest responsive signal upon the addition of WT-EBNA1 ( Fig. 2a , 2b, 2c, Sup. Fig.   21 ), a 8.8-fold emission enhancement (ϕinitial = 4 %, ϕ4M WT-EBNA1 = 23%, Sup. Fig. 19 and 20) and 25 nm emission blueshift. A 4.7 times emission enhancement was seen in the titration experiment for L2P3, and no emission enhancement/quenching was observed for L2P2 upon addition of 4 M WT-EBNA1 (Sup. Fig. 21 ). The affinity strength for a probe to its binding protein can be defined as the binding constant and binding ratio. The aforementioned binding constant (log Ka) was calculated for L2P2-L2P4 to WT-EBNA1 (Sup. Fig. 21 ). The logarithm of the fluorescence ratio demonstrated a linear relationship with that of the protein concentration. The value of log Ka was calculated to be 5.50 and 6.82 for L2P3 and L2P4 respectively, and both of the binding ratios were found to be 1:1. Considering the strongest binding of L2P4 to WT-EBNA1, we then further investigated the binding selectivity of L2P4 to WT-EBNA1 in the presence of various proteins ( Fig.   2c ) and biologically relevant metal ions/small molecules (Zn 2+ , citrate etc) (Sup. Fig. 22 It is well established that when an environment-sensitive fluorophore is conjugated to peptides with specific targeting, subsequent protein binding will give rise to the emission intensity and a strong blue-shift will occur due to the dramatic change in excited state dipole-moments. It is well known now that the dual fluorescence of 4-(N,N-dimethylamino)benzonitrile (DMABN) arises due to an emission from the local excited (LE) state and an "anomalous" red-shifted emission from the ICT state [15] [16] [17] . Among the numerous DMABN analogues reported to date, pyridine derivatives have been a focus of particular interest, especially in the determination of cell microviscosity 18 .
With this in mind we proposed that a fluorescent probe consisting of an ICT state pyridine derivative fluorophore and a nucleus-permable EBNA1-specific peptide, which generates ICT characterized emission after binding with EBNA1, could prevent the homodimerization of EBNA1, and meanwhile imaging on nucleus level in EBV-positive cells.
The absorption spectrum of L2P4 was measured in various solvents (Sup. Fig. 24 ). The spectra showed two absorption bands at 274 nm and ~500 nm, which corresponded to the transition from ground state to LE and ICT states, respectively 17, 19 . The maximum absorption band was slightly red-shifted in polar solvents. L2P4 demonstrated dual fluorescence upon excitation, a weak but higher energy emission at 560 nm arising from the LE state and a strong emission at ~625 nm from P r o o f the ICT state were both observed ( Fig. 2a, 2d, 2e ). The fluorescence emission of LE band was solvent-independent, while the ICT band exhibited a marked dependence on solvent polarity, progressively blue shifted with the decreasing of solvents polarity ( Fig. 2e ). Besides, the emission decay of L2P4 was measured as shown in Sup. Fig. 26 and Fig. 2f (upper, ex = 475 nm, monitored at 625 nm) and the emission lifetime of L2P4 in different solvents was concluded in Sup. Table 5 .
The observed shorter lifetime (~0.5 ns) was corresponded to the LE emission, and the ICT band also demonstrated a longer lifetime (3.8 ns).
Nuclear in vitro imaging of L2P4. The in vitro imaging of L2P2, L2P3 and L2P4 in HeLa, CNE2, C666-1 and NPC43 cells were carried as shown in figure 3 . HeLa is EBV-negative human cervical carcinoma cell line, CNE2 is EBV-negative nasopharyngeal carcinoma cell line, C666-1 is EBVpositive nasopharyngeal carcinoma cell line, and NPC43 is the newly derived EBV-positive nasopharyngeal carcinoma cell line which was established from a surgical resected NPC tissue from a male patient (64 years old with Stage III recurrent NPC). As previously discussed, we incorporated a NLS sequence RrRK into P3 and P4 to help their nucleus permeability 20, 21 . The cellular uptake and localization of the three probes was evaluated independently using confocal imaging and flow cytometry ( Fig. 3 , Sup. Fig. 28, 29, 30 ). From these experiments, L2P4 was found to have a better cellular uptake compared with the other two probes in both HeLa and C666-1 cells (Sup. Fig. 28 ). With the significant contribution of RrRK, the subcellular localization of L2P3 and L2P4 can be observed in the nucleus of EBV-positive cells (C666-1 and NPC43 cells), whilst L2P2 can only be noticed in cytoplasm in the tested cells, suggesting L2P3 and L2P4 could localize on the EBV-positive cell-nucleus. In addition, two videos of L2P4 in HeLa and C666-1 cells were performed (Conc.: 10 M) (Sup. Video 1 and 2). Images in the video were taken once per minute and 60 images for the first hour after drug treatment were collected to make the video.
The video showed a dynamic and intuitive visual of the selective nucleus localization of L2P4 in EBV-positive cells.
Selective toxicity of L2P4 towards EBV+ cells. EBNA1 can only facilitate DNA replication of EBV by forming homodimers, thus blocking dimer formation provides a route by which to kill EBV-infected tumour cells. As is well known, the EBNA1 dimer is formed through the YFMVFmediated interface, and this can be examined by MBS (3-maleimidobenzoyl Nhydroxysuccinimide ester, an amine-to-sulfhydryl crosslinker that contains NHS-ester and maleimide reactive groups) cross-linked dimerization assay. The MBS mediated protein crosslinking effect was represented as a ratio of dimer/monomer. The importance of YFMVF on dimerization was further investigated in the WT-EBNA1 and EBNA1 mutants (EBNA1-Y561A, EBNA1-M563A, EBNA1F565A and EBNA1-3A) by its homodimerization efficiency. The results demonstrated that the dimerization efficiency was greatly decreased in EBNA1-3A, and also, a relative slight decreasing in the efficiency was observed in the other three point mutants (Sup. Fig.   27 ). Consistent with this observation and the luminescence titration experiment, the MBS crosslinked dimerization assay was also obviously inhibited by the designed probes as shown in Fig. 4a , 4b, 4c, 4d (P<0.001).
Considering the strong binding of L2P4 to WT-EBNA1 and the selective nuclear in vitro imaging, we sought to evaluate if L2P4 could deliver selective and efficient cytotoxicity towards EBVpositive cells. The MTT cytotoxicity assay of the three peptides (P2-P4, Sup. Fig. 31 ) and three peptide conjugates (L2P2-L2P4, Fig. 4e-4j ) was carried out in three kinds of EBV-negative (MRC- Fig. 32, 33, 35a ), indicating that neither P4 nor L2P4 exhibit a toxic effect in vivo. C666-1 cell xenograft growth was effectively inhibited while the growth of HeLa cell xenograft was unaffected by treatment with P4/L2P4 (Fig. 5d , Sup. Fig. 35b ). By day 7, treatment with P4-L, P4-H and L2P4-H on C666-1 cell xenografts has led to significant decreases in tumour volume and at the end of the experiment (day 21), the average tumour volumes of mice were decrease by 65.7%, 65.5% and 92.3% (P<0.05, P<0.005 and P<0.001) respectively, when compared to control (Fig. 5d, Sup. Fig. 34 ). In the HeLa cell xenografts, there was no significant difference in the average tumour volume of mice treated with P4/L2P4 (low or high dose) and control after 18 days (Sup. Fig. 35b ). At the end of the experiment, mice were sacrificed and tumours were excised and weighed, average tumour weights were decreased on C666-1 cell xenografts after treatment with P4-L, P4-H and L2P4-H by 72.6%, 86.6% and 92.8% (NS, P<0.05 and P<0.005) respectively, when compared to control (Fig. 5a, 5b, 5c and 5e ). While in the HeLa cell xenografts, there was no obvious difference in the average tumour weights (Sup. Fig. 35c, 36) .
The significant and selective inhibition of P4/L2P4 on EBV-positive tumour confirmed their EBVtargeting specificity and indicated the conjugation of L2 to P4 does not affect its tumour inhibitory effect.
from L2P4 treated tumours (Fig. 5f ), indicating the presence of signal 48 hours post-intra-tumoural injection. As expected, no fluorescent signal was detected in control or P4 treated tumours.
Discussion
Our initial MD studies suggested that a network of hydrophobic interactions and salt bridging mediates the binding of L2P4 to the dimeric interface of EBNA1 (Fig. 1) . The selective and strong binding of L2P4 to EBNA1 was further confirmed using luminescence titration experiment (Fig. 2) . L2P4 was found to localise in the nucleus of EBV-positive cells, but not that of EBV-negative cells. The observed selective emission of L2P4 on nucleus was generated by its binding with EBNA1 ( Fig. 3 ).
Our study also revealed that EBNA1 mutants (especially EBNA1-3A) were not able to undergo homodimerization (Sup. Fig. 27 ), emphasizing the importance of the dimeric interface (YFMVF) on EBNA1 dimer formation. The analysis of the WT-EBNA1 dimerization efficiency upon addition of the designed probes using a MBS crosslinked dimerization assay showed that the probes can significantly interfere with EBNA1 dimer formation ( Fig.   4a, 4b, 4c, 4d ). Extensive cytotoxicity assays performed against both EBV positive and negative cells demonstrated the significant and selective inhibition of L2P4 on EBV-positive cells, more importantly, revealed the reason for the selective cytotoxicity is the inhibition on EBNA1 dimerization process ( Fig. 4e-4j ). Finally, studies of L2P4 on mice carrying C666-1 and HeLa cell xenografts confirm that it has EBV-targeting specificity and indicated that our designed probe can be successfully applied to target and inhibit the growth of EBV-positive tumours in vivo (Fig. 5 ).
Our data clearly demonstrates that L2P4 can selectively inhibit EBV-positive tumours-both in vitro and in vivo, and that it does this via interfering with EBNA1 homodimerization. We are confident that our present work will Luminescence titration analysis. The measurement of the binding constant and selectivity of the designed probes was performed by luminescence titration analysis. It was conducted with gradually addition of various analytes (e.g. WT-EBNA1, EBNA1 mutants, BSA and metal ions), which will be ceased either when the volume of added analytes totalled 5% of the probes or the influence on luminescence was saturated.
Protein samples preparation. Five protein samples were used during this work. WT-EBNA1 protein (379-641 a.a.) fused with glutathione S-transferase was expressed in Escherichia coli and purified by glutathione sepharose 4B rinse (GE Healthcare Dharmacon), afterwards 5 g EBNA1 was prepared and incubated with MBS at 37C for 10 minutes. The protein was separated on an SDS-PAGE gel, transferred onto the nitrocellulose membrane and blotted by antibodies (#RG001040, Solarbio, Bioscience & Technology Co., LTD). EBNA1 mutant proteins were prepared by mutation of YFMVF to FFAVA (yielding EBNA1-3A mutant) or conservative point mutation of Y561, M563, F565 to A (yielding EBNA1-Y561A, EBNA1-M563A and EBNA1-F565A) through site-directed mutagenesis. Afterwards, the cells were incubated with the probes as indicated, and then washed with PBS several times.
Cellular uptake was evaluated with flow cytometry under 488 nm excitation generated by an argon laser. The emission was obtained by using FL2-H (log). 10000 events were analyzed to get the cellular uptake.
In vitro imaging and Co-staining. Cells were incubated for 6 hours before monitoring/imaging. For co-staining experiments after incubation cells were further treated with 1nM nucleus lyso Green DND-26 tracker/mito Green Cytotoxicity test. The MTT viability assay was performed according to standard methods. In brief, cells (310 3 / well) were seeded in 96-well plates 24 hours prior to exposure to the probes. The cells were incubated with the probes in the dark for another 24 hours. The cytotoxicity was determined by the MTT reduction assay. The cell monolayers were rinsed with phosphate-buffered saline (PBS) and then incubated with 50 uL MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (0.5 mg/ mL) at 37C for 3 hours. Then the media were removed, and 100 uL of DMSO solubilizing reagent was added and shaken for 30 minutes to dissolve the formed formazan crystals in the living cells. Statistical analysis. The intensity of the protein bands and raw images were measured by Gel-Pro Analyzer to obtain the average of three independent experiments, showed as mean ± S.D. The results were presented as the column plot operated by GraphPad Prism 5.0. Single factor analysis of variance was used to detect the significance of difference. The absorbance of the formed formazan crystals in cytotoxicity test was measured at dual wavelength, 540nm and 690nm, on a Labsystem Multiskan microplate reader (Merck Eurolab, Switzerland). Each dosed concentration was performed in triplicate wells, and repeated twice for the MTT assay. Data were shown as mean ± S.D. Statistical analyses of tumour size and volume in the animal studies were conducted using the Student's t-test. Results of P < 0.05 were considered significant. Data were expressed as mean ± SEM.
Nude mice carrying C666-1/HeLa xenograft and intra-tumoural injection (
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with the EPSRC open data policy from DOI: 10.15128/r2v692t620b. Fig. 25 ). The emission band gradually decreased as the pH was lowered from 7 to 2. This finding is consistent with the characteristic of an ICT emission, which is the ICT state emision decreases at lower pHs because the nitrogen atoms becomes protonated in lower pHs and its lone pair is not avaliable to generate an ICT excited state; (e) The emission spectra of L2P4 in solvatochromism study with increasing solvent polarity; (f) Emission lifetime decay of L2P4 upon binding with WT-EBNA1 (upper) and solvatochromism (lower) with increasing solvent polarity (ex = 475 nm). Comparatively large LE emission decay and corresponding smaller ICT decay was found in less polar solvents, indicating a smaller dipole moment and cosequently an upshift of the ICT state. Additionaly, the emission lifetime of L2P4 upon binding with WT-EBNA1 was found similar to that in polar solvents. 
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